EDITORIAL
Year : 2023 | Volume
: 66 | Issue : 3 | Page : 443-
From the Editor's desk
Bharat Rekhi
MD, DNB, MIAC, FICP, MCAP(Affl.), FRC-Path, Professor/Pathologist, Department of Surgical Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India
Correspondence Address:
Bharat Rekhi
MD, DNB, MIAC, FICP, MCAP(Affl.), FRC-Path, Professor/Pathologist, Department of Surgical Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India
India
How to cite this article:
Rekhi B. From the Editor's desk.Indian J Pathol Microbiol 2023;66:443-443
|
How to cite this URL:
Rekhi B. From the Editor's desk. Indian J Pathol Microbiol [serial online] 2023 [cited 2023 Sep 30 ];66:443-443
Available from: https://www.ijpmonline.org/text.asp?2023/66/3/443/382465 |
Full Text
Dear Readers,
I am happy to inform you that the impact factor of our journal has escalated to 1.0. This is a result of the collaborative efforts of all the earlier editors, associate and assistant editors; the active editorial members, reviewers, authors, and the technical support team. I look forward to this continuing support for further enhancement of the impact of our journal.
This issue features original research spanning from the value of time-honored histopathological parameters, to the addition of newer markers for prognostication and prediction; value addition of techniques, such as next-generation sequencing (NGS), for unraveling mutations involved in the pathogenesis of certain aggressive tumors that could probably be targeted for a therapeutic benefit and the potential of stem cell markers as a guide to neoadjuvant therapy in certain carcinomas.
Fonseca et al.[1] have demonstrated the prognostic and predictive value of certain routine histomorphological parameters, including the Brandwein–Gensler risk model in early-stage oral squamous cell carcinomas.
Erdogan et al.[2] observed certain underlying mutations in uterine carcinosarcomas using NGS that could provide additional insights toward potential targeted therapies for these relatively aggressive tumors.
Bedeer et al.[3] noted that increased expression of chemokine receptor type 4 (CXCR4) and decreased expression of peroxisome proliferator activator-gamma (PPAR-γ) are associated with increased grade, advanced stage, and vascular invasion in colorectal carcinomas.
In their study, Mohamedali et al.[4] observed that a strong expression of EZH2 and weak expression of H3K27me3 are associated with high grade, increased proliferation, and invasive behavior in cases of urothelial carcinomas.
Gucin et al.[5] have shown a possible role of certain stem cell markers as a guide to neoadjuvant chemotherapy in breast carcinomas.
I hope you all feel enriched with the scientific content of this issue and we continue receiving more of high-quality research, especially original and review articles.
References
| 1 | Fonseca D, Khemani R, Pasam MK, Tagore R, Rao BV, Kodandapani S, et al. Histological risk score and its role in predicting recurrence in early-stage oral squamous cell carcinomas. Indian J Pathol Microbiol 2023;66:444-8. |
| 2 | Erdoğan EG, Yalta TD, Can N, Süt N, Taştekin E, Usta U, et al. Clinicopathological and molecular analyses of uterine carcinosarcomas using next-generation sequencing: A single-center experience. Indian J Pathol Microbiol 2023;66:449-55. |
| 3 | Bedeer AE, Heabah NA. Evaluation of C-X-C chemokine receptor type 4 (CXCR4) and Peroxisome proliferator-activated receptor gamma (PPAR-γ) expression in colorectal carcinoma: Relation to the available clinicopathological parameters. Indian J Pathol Microbiol 2023;66:465-471. |
| 4 | Mohamedali R, Mitra S, Mandal S, Nayak P, Adhya AK, Purkait S. Expression of EZH2 and H3K27me3 predicts tumor biology of urothelial carcinoma. Indian J Pathol Microbiol 2023;66:488-494. |
| 5 | Gucin Z, Buyukpinarbasili N, Gecer MO, Ersoy YE, Turk HM, Yildiz S, et al. Stem cell markers: A guıde to neoadjuvant therapy ın breast carcinomas. Indian J Pathol Microbiol 2023;66:495-501. |
|
